Serum anti-GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening

Mei Ling Xu, Hyoung Jin Kim, Seung Cheol Kim, Woong Ju, Yun Hwan Kim, Kyu Ho Chang, Hong Jin Kim

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Recent studies have indicated that a certain level of autoantibodies may be essential for maintaining good health as well as preventing cancer development, and that the levels of serum autoantibodies can decline during malignant progression. The aim of the present study was to identify such an autoantibody-based biomarker for screening cervical lesions. An autoantigen reactive with healthy female sera was detected in the cytosolic fraction of HeLa cells, a cervical cancer cell line, and identified. Serum immunoglobulin (Ig)-G and IgM levels against the purified autoantigen in normal, cervical intraepithelial neoplasias (CINs) I, II and III, and cervical cancer were compared using ELISAs. The autoantigen in HeLa cells was identified to be GAPDH. The serum levels of anti-HeLa-GAPDH IgG decreased with increasing severity of cervical lesions, and similar decreases in IgM levels were revealed. Notably, the anti-HeLa-GAPDH IgG level was discovered to discriminate cervical cancer from normal samples with 80.0% sensitivity and 96.6% specificity. The serum anti-HeLa-GAPDH autoantibody level, as a single parameter, is a promising serum biomarker for screening cervical lesions.

Original languageEnglish
Pages (from-to)255-264
Number of pages10
JournalOncology Letters
Volume18
Issue number1
DOIs
StatePublished - 2019

Keywords

  • Autoantibody
  • Cervical cancer
  • Cervical intraepithelial neoplasia
  • Glyceraldehyde 3-phosphate dehydrogenase
  • Serum biomarker

Fingerprint

Dive into the research topics of 'Serum anti-GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening'. Together they form a unique fingerprint.

Cite this